Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 762-764

  Kempf, Dale J ^a   Waring, Jeffrey F ^a   Morfitt, David C ^a   Werner, Paige ^a   Ebert, Brian ^a   Mitten, Michael ^a   Nguyen, Bach ^a   Randolph, John T ^a   DeGoey, David A ^a   Klein, Larry L ^a   Marsh, Kennan ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 681799; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ANIMAL EXPERIMENT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE PREDISPOSITION; HYPERBILIRUBINEMIA; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; HIV PROTEASE INHIBITORS; HYPERBILIRUBINEMIA; RATS; RATS, GUNN;

EID: 31944444784     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.762-764.2006     Document Type: Article

References (7)

1. Campbell, S. D., S. M. de Morais, and J. J. Xu. 2004. Inhibition of the human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem.-Biol. Interact. 150:179-187.
2. Iyanagi, T., T. Watanabe, and Y. Uchiyama. 1989. The 3- methylcholanthrene-inducible UDP-glucuronosyltransferase deficiency in the hyperbilirubinemic rat (Gunn rat) is caused by a -1 frameshift mutation. J. Biol. Chem. 264:21302-21307.
3. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
4. O'Mara, E., V. Mummaneni, B. Burchell, D. Randall, N. Sagali, T. Tanner, A. Schuster, M. Geraldes, R. Raymond, and S. Kaul. 2000. Relationship between uridine diphosphate glucuronosyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1645. American Society for Microbiology, Washington, D.C.
5. Randolph, J. T., P. Huang, C. Flentge, D. A. DeGoey, W. Flosi, D. Grampovnik, C. Yeung, H. J. Chen, L. L. Klein, T. Dekhtyar, H. Mo, L. Colletti, W. Kati, J. M. Schmidt, T. Turner, K. C. Marsh, A. Molla, and D. J. Kempf. 2004. A-681799, a novel HIV protease inhibitor. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., abstract F-485. American Society for Microbiology, Washington, D.C.
6. Zhang, D., T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys. 2005. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33:1729-1739.
7. Zucker, S. D., X. Qin, S. D. Rouster, F. Yu, R. M. Green, P. Keshavan, J. Feinberg, and K. E. Shertnan. 2001. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. USA 98:12671-12676.